CELSET Launches SOLTOX Botulinum Toxin Brand for International Markets
CELSET says it has launched SOLTOX, a Korean botulinum toxin Type A brand, for international markets.
Related stories
Integer Holdings Reports Q3 Revenue of $449.7M
Integer Holdings reported Q3 revenue of $449.7M, compared with a FactSet estimate of $456.9M.
M impact | EQUITY | Oct 29, 2026, 12:17 PM UTC
Establishment Labs Posts Q3 Net Loss of $0.35 per Share
The company reported a Q3 net loss of $0.35 per share, versus FactSet's estimate of a $0.26 loss.
M impact | EQUITY | Oct 29, 2026, 12:11 PM UTC
Mastercard 3Q Cross-Border Volume Rose 11%
M impact | EQUITY | Oct 29, 2026, 12:06 PM UTC
Mastercard Q3 Cross-Border Volume Grows 11%
Mastercard reported Q3 cross-border volume growth of 11% on a local currency basis.
M impact | EQUITY | Oct 29, 2026, 12:06 PM UTC
Salam International Transport and Trading reports Q3 profit of 685,146 dinars
M impact | EQUITY | Oct 29, 2026, 12:06 PM UTC
Bankwell Financial Q3 adjusted EPS $1.86, revenue $35.3 million
Bankwell Financial reported Q3 adjusted EPS of USD 1.86 and revenue of USD 35.3 million.
M impact | EQUITY | Oct 29, 2026, 12:06 PM UTC